German Health Cost Curbs "Imperative"

17 March 1997

German federal Health Minister Horst Seehofer says economies areimperative after the health funds posted a 1996 deficit of 6.3 billion Deutschemarks ($3.70 billion), 3.9 billion marks for western Germany and 2.4 billion marks for the eastern states. The deficit is however lower than expected.

The main legislative revisions planned to support this policy can be forced through by the coalition government without the agreement of the parliamentary upper house, and will increase pressure on the funds to reach stricter agreements on economies with the medical profession and other health care providers.

Also, the tendency for insured people to switch to funds offering better value for money is more extensive than expected. 1996 spending in several health service sectors rose above 5%, with drug spending up 6.3%. Average spending on the full range of treatments rose 3% against a rise in contribution income of only 1.4%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight